1. Home
  2. ZGN vs AKRO Comparison

ZGN vs AKRO Comparison

Compare ZGN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZGN
  • AKRO
  • Stock Information
  • Founded
  • ZGN 1910
  • AKRO 2017
  • Country
  • ZGN Italy
  • AKRO United States
  • Employees
  • ZGN N/A
  • AKRO N/A
  • Industry
  • ZGN Apparel
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZGN Consumer Discretionary
  • AKRO Health Care
  • Exchange
  • ZGN Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • ZGN 2.0B
  • AKRO 2.4B
  • IPO Year
  • ZGN N/A
  • AKRO 2019
  • Fundamental
  • Price
  • ZGN $7.50
  • AKRO $32.38
  • Analyst Decision
  • ZGN Strong Buy
  • AKRO Strong Buy
  • Analyst Count
  • ZGN 1
  • AKRO 7
  • Target Price
  • ZGN $18.70
  • AKRO $43.20
  • AVG Volume (30 Days)
  • ZGN 1.1M
  • AKRO 554.0K
  • Earning Date
  • ZGN 09-18-2024
  • AKRO 11-08-2024
  • Dividend Yield
  • ZGN 1.71%
  • AKRO N/A
  • EPS Growth
  • ZGN 14.68
  • AKRO N/A
  • EPS
  • ZGN 0.42
  • AKRO N/A
  • Revenue
  • ZGN $2,101,802,207.00
  • AKRO N/A
  • Revenue This Year
  • ZGN $1.02
  • AKRO N/A
  • Revenue Next Year
  • ZGN $4.16
  • AKRO N/A
  • P/E Ratio
  • ZGN $18.12
  • AKRO N/A
  • Revenue Growth
  • ZGN 17.68
  • AKRO N/A
  • 52 Week Low
  • ZGN $7.13
  • AKRO $13.86
  • 52 Week High
  • ZGN $15.26
  • AKRO $37.00
  • Technical
  • Relative Strength Index (RSI)
  • ZGN 37.59
  • AKRO 55.64
  • Support Level
  • ZGN $7.13
  • AKRO $31.12
  • Resistance Level
  • ZGN $7.84
  • AKRO $35.11
  • Average True Range (ATR)
  • ZGN 0.27
  • AKRO 1.74
  • MACD
  • ZGN 0.01
  • AKRO 0.11
  • Stochastic Oscillator
  • ZGN 37.76
  • AKRO 53.31

About ZGN Ermenegildo Zegna N.V.

Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. It operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment; and the Tom Ford Fashion segment. It generates the majority of its revenue from the Zegna segment.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: